NMDA受体与α_(2)肾上腺素受体参与神经精神疾病的分子机制研究进展  

Research progress on molecular mechanism underlying neuropsychiatricdiseases involving NMDA receptor and α_(2) adrenergic receptor

作　　者：章文欣 周冬雨 韩奕 季然 艾琳 谢安 翟晓静 曹君利[1,2] 张红星 ZHANG Wen-xin;ZHOU Dong-yu;HAN Yi;JI Ran;AI Lin;XIE An;ZHAI Xiao-jing;CAO Jun-li;ZHANG Hong-xing(Jiangsu Province Key Laboratory of Anesthesiology,Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology,Key Laboratory of Research and Evaluation of Narcotic Psychotropic Drugs of the State Medical Products Administration,Xuzhou Jiangsu 221004,China;Dept of Anesthesiology,Affiliated Hospital of Xuzhou Medical University,Xuzhou Jiangsu 221002,China)

机构地区：[1]江苏省麻醉学重点实验室,江苏省麻醉与镇痛应用技术重点实验室,国家药品监督管理局麻醉精神药物研究与评价重点实验室,江苏徐州221004 [2]徐州医科大学附属医院麻醉科,江苏徐州221002

出　　处：《中国药理学通报》2024年第12期2206-2212,共7页Chinese Pharmacological Bulletin

基　　金：科技创新2030重大项目(No 2021ZD0203100);国家自然科学基金资助项目(No 31970937,82271255);江苏省研究生科研与实践创新计划项目(No KYCX22_2918、2932)。

摘　　要：谷氨酸与去甲肾上腺素及其对应受体分别构成谷氨酸能系统和去甲肾上腺素能系统,二者在多种神经精神疾病过程中发挥重要作用,并且存在密切对话。该文回顾了高级中枢神经系统中谷氨酸受体——N-甲基-D-天冬氨酸受体(Nmethyl-D-aspartate receptor,NMDA-R)和肾上腺素受体——α_(2)肾上腺素受体(alpha 2 adrenergic receptor,α_(2)-AR)参与神经精神疾病的具体分子机制,以及二者可能的对话机制,对深入认识两种受体相关神经精神疾病的神经生物学机制、药物研发和优化临床治疗方案具有重要意义。Glutamate,norepinephrine,and their receptors comprise the glutamatergic and norepinephrine systems,which mutually affect each other and play essential roles in mediating various neuropsychiatric diseases.This paper reviews the functions of N-methyl-D-aspartate receptor(NMDA-R)andα2-adrenergic receptor(α2-AR)and their functional crosstalk at the molecular level in brain in common neuropsychiatric diseases,which would benefit our understanding of neuropathophysiology of psychiatric diseases,drug development and optimization of clinical neuropsychopharmacology.

关 键 词：NMDA受体 α_(2)肾上腺素受体 脑源性营养因子 抑郁症 阿尔茨海默病 神经生物学 

分 类 号：R322.81[医药卫生—人体解剖和组织胚胎学] R392.11[医药卫生—基础医学] R745.7R749.42